A discussion between Dr. Peter Anglin and Dr. Nathalie Johnson (March 2023)

Dr. Anglin and Dr. Johnson review the recently published Canadian guidelines for front-line CLL. They focus on different patient subgroups, including those with high-risk features such as del(17p) and TP53 mutations, complex cytogenic, unmutated IGHV, as well as those with good performance status and favorable genetic profiles. Continuous vs fixed treatment duration is assessed in the context of comorbidities and patient preferences.

Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON

Nathalie A. Johnson, MD, PhD, FRCPC, Associate Professor McGill University, Department of Medicine, Jewish General Hospital, Montreal, QC

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.